Matching articles for "age-related macular degeneration"
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • January 22, 2024; (Issue 1694)
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration...
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration (AMD).
Avacincaptad pegol is the second complement
inhibitor to be approved in the US for this indication;
pegcetacoplan (Syfovre), a complement C3 and C3b
inhibitor, was approved earlier.
Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • April 3, 2023; (Issue 1673)
The FDA has approved the complement C3 inhibitor
pegcetacoplan (Syfovre – Apellis) for treatment of
geographic atrophy (GA) secondary to age-related
macular degeneration (AMD). Given as a series...
The FDA has approved the complement C3 inhibitor
pegcetacoplan (Syfovre – Apellis) for treatment of
geographic atrophy (GA) secondary to age-related
macular degeneration (AMD). Given as a series of
monthly or every-other-month (EOM) intravitreal
injections, it is the first drug to become available for
use in patients with atrophic dry AMD. Subcutaneous
pegcetacoplan was approved earlier as Empaveli for
treatment of paroxysmal nocturnal hemoglobinuria.
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • May 2, 2022; (Issue 1649)
The FDA has approved Susvimo (Genentech), a
refillable permanent ocular implant containing the
vascular endothelial growth factor (VEGF) inhibitor
ranibizumab, for treatment of neovascular (wet)...
The FDA has approved Susvimo (Genentech), a
refillable permanent ocular implant containing the
vascular endothelial growth factor (VEGF) inhibitor
ranibizumab, for treatment of neovascular (wet) age-related
macular degeneration (nAMD) in patients who
have previously responded to at least two intravitreal
injections of a VEGF inhibitor. Ranibizumab intravitreal
injection (Lucentis) has been available since 2006 for
monthly treatment of nAMD. The FDA has approved
ranibizumab-nuna (Byooviz), a biosimilar of Lucentis
and the first ophthalmologic biosimilar; it will be
available in June 2022.
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • March 21, 2022; (Issue 1646)
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of neovascular
(wet) age-related macular degeneration (nAMD) and
diabetic macular edema (DME). It is the first drug to
become available in the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available for treatment of
nAMD and DME (see Table 2).
Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • March 9, 2020; (Issue 1593)
We reviewed brolucizumab (Beovu – Novartis) for treatment
of neovascular (wet) age-related macular degeneration in our
February 10 issue. On February 23, the American Society of
Retina Specialists reported...
We reviewed brolucizumab (Beovu – Novartis) for treatment
of neovascular (wet) age-related macular degeneration in our
February 10 issue. On February 23, the American Society of
Retina Specialists reported that 14 patients who received the
drug have developed retinal vasculitis, a potentially vision-threatening
complication.
Brolucizumab (Beovu) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • February 10, 2020; (Issue 1591)
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related...
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related macular
degeneration (AMD). It is the fourth VEGF inhibitor to
be approved in the US for this indication; bevacizumab
(Avastin, and others), a VEGF inhibitor FDA-approved
for treatment of breast cancer and other malignancies,
has been used off-label for this indication for years.
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • December 2, 2019; (Issue 1586)
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
VEGF Inhibitors for AMD and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • March 16, 2015; (Issue 1464)
Vascular endothelial growth factor (VEGF) is a principal
mediator of neovascularization in wet age-related
macular degeneration (AMD) and diabetic macular
edema. It induces angiogenesis and increases...
Vascular endothelial growth factor (VEGF) is a principal
mediator of neovascularization in wet age-related
macular degeneration (AMD) and diabetic macular
edema. It induces angiogenesis and increases vascular
permeability and inflammation. VEGF inhibitors reduce
leakage from blood vessels, prevent proliferation of
new abnormal vessels, decrease swelling of the retina,
and improve visual acuity in patients with neovascular
(wet) AMD and diabetic macular edema. These drugs
are given as periodic intravitreal injections with topical
anesthesia.
Nutritional Supplements for Age-Related Macular Degeneration Revisited
The Medical Letter on Drugs and Therapeutics • June 24, 2013; (Issue 1419)
The results of the Age-Related Eye Disease Study 2
(AREDS2) have now been published. The primary purpose
of the study was to evaluate the efficacy and safety
of the carotenoids lutein and zeaxanthin and...
The results of the Age-Related Eye Disease Study 2
(AREDS2) have now been published. The primary purpose
of the study was to evaluate the efficacy and safety
of the carotenoids lutein and zeaxanthin and the
omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA)
in reducing the risk of developing advanced age-related
macular degeneration (AMD). A secondary goal was to
test the effects of reducing the amount of zinc and eliminating
beta carotene from the original AREDS formulation.
Beta carotene has been shown to increase the
risk of lung cancer in smokers and former smokers.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • November 1, 2012; (Issue 123)
Drugs for glaucoma, age-related macular degeneration,
bacterial conjunctivitis, and dry eyes are
reviewed here. Drugs for the treatment of allergic conjunctivitis
will be reviewed in a future issue...
Drugs for glaucoma, age-related macular degeneration,
bacterial conjunctivitis, and dry eyes are
reviewed here. Drugs for the treatment of allergic conjunctivitis
will be reviewed in a future issue of
Treatment Guidelines on Drugs for Allergic Disorders.
Aflibercept (Eylea) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • February 6, 2012; (Issue 1383)
The FDA has approved aflibercept (a flib’ er sept;
Eylea – Regeneron) for treatment of neovascular (wet)
age-related macular degeneration...
The FDA has approved aflibercept (a flib’ er sept;
Eylea – Regeneron) for treatment of neovascular (wet)
age-related macular degeneration (AMD).
Nutritional Support for Macular Degeneration
The Medical Letter on Drugs and Therapeutics • August 9, 2010; (Issue 1344)
An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new...
An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new product] builds on the original PreserVision Eye Vitamin AREDS Formula, the only formula proven to slow the progression of moderate-to-advanced AMD.”
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • January 1, 2010; (Issue 89)
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly...
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • January 1, 2007; (Issue 53)
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some...
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Ranibizumab (Lucentis) for Macular Degeneration
The Medical Letter on Drugs and Therapeutics • October 23, 2006; (Issue 1246)
The FDA has approved ranibizumab (Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab...
The FDA has approved ranibizumab (Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab (Avastin), which is FDA-approved for intravenous treatment of metastatic colorectal cancer and nonsmall cell lung cancer, but has also been used off label for intravitreal treatment of neovascular AMD.
Antioxidant Vitamins and Zinc for Macular Degeneration
The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)
High doses of beta carotene, vitamin C, vitamin E and zinc oxide are now being promoted to the general public to "preserve eye health" (Ocuvite PreserVision), "promote retinal and visual health" (VisiVite) and...
High doses of beta carotene, vitamin C, vitamin E and zinc oxide are now being promoted to the general public to "preserve eye health" (Ocuvite PreserVision), "promote retinal and visual health" (VisiVite) and "preserve healthy vision" (ICaps). Internet advertisements for these products all refer to a clinical trial, the Age-Related Eye Disease Study (AREDS), which was conducted in patients with age-related macular degeneration (AMD).